ABSTRACT: Toll-like receptor 2 (TLR2) is a target for immune system stimulation during cancer immunotherapy and a cell-surface marker for pancreatic cancer. To develop targeted agents for cancer imaging and therapy, we designed, synthesized, and characterized 13 novel, fully synthetic high affinity TLR2 agonists. Analogue 10 had the highest agonist activity (NF-κB functional assay, EC 50 = 20 nM) and binding affinity (competitive binding assay, K i = 25 nM). As an immune adjuvant, compound 10 stimulated the immune system in vivo by generation and persistence of antigen-specific CD8+ T cells indicating its potential use in cancer immunotherapy. After conjugation of near-infrared dye to 10, agonist activity (EC 50 = 34 nM) and binding affinity (K i = 11 nM) were retained in 13.
■ INTRODUCTION
The discovery of ligands and small molecule synthetic compounds that specifically activate Toll-like receptor 2 (TLR2) has raised interest in this cell-surface receptor as a potential target for the development of new therapies, including the treatment of cancer.
1 TLR2 has a role in activation and regulation of the innate immune system, and targeted stimulation of this receptor has been used to augment cancer immunotherapy.
1b,2 Although TLR2 is predominantly expressed in tissues involved in immune function, the expression profile varies among tissues and cell types.
3 TLR2 is a type I transmembrane glycoprotein characterized by an external antigen recognition domain comprising a highly conserved leucine-rich repeat motif, a transmembrane domain, and a cytoplasmic Toll/interleukin-1 (TIR) receptor homology signaling domain. Intracellular signaling is activated by agonist binding and is facilitated by the formation of the cytoplasmic TIR domain through heterodimerization with either TLR1 or TLR6.
4 TLR2 is a pattern recognition receptor with the ability to recognize pathogen-associated molecular patterns (PAMPs). 5 Stimulation by PAMPs initiates signaling cascades that activate NF-κB transcription factors inducing the secretion of proinflammatory cytokines and effector cytokines directing the immune response. 5c The potential use of synthetic TLR2 agonists for the enhancement of cancer immunotherapy is an active area of research.
6 There are four mechanisms by which TLR2 stimulation may produce significant antitumor activity: enhancement of the innate immunity, enhancement of T-cell immunity, enhancement of cytotoxic antibody function, and induction of apoptosis in TLR2-positive tumors.
1b Examples include the TLR2 induction of tumor necrosis factor-α (TNF-α), increasing the production of nitric oxide synthase (iNOS) and thus inducing apoptosis of chemotherapy-resistant tumor cells, 7 reduction of bladder tumor growth by TLR2 agonist SMP-105, 8 and a combination therapy of macrophage-activating lipopeptide 2 kDa (MALP-2) and gemcitabine that increased the survival rates of incompletely resectable pancreatic cancers in a phase I/II trial. 9 We have previously reported the use of TLR agonists as immune adjuvants that can increase the magnitude and duration of peptide vaccine-induced T cell responses, 10 as demonstrated by our TriVax vaccine that elicits potent protective antitumor immunity as well as remarkable therapeutic effects against melanoma. 11 In an effort to improve the less than 6% 5-year survival rate for pancreatic cancer, 12 we are investigating the potential of TLR2 ligands for use in targeted pancreatic cancer imaging and treatment. Improved survival rates are associated with the surgical resection of the primary tumor if the tumor tissue is completely removed at the margins. 13 However, it is a high risk procedure with a low success rate due to difficulty in clearly identifying tumor tissue from normal tissue, resulting in positive resection margins (R 1 ).
14 The development of new intraoperative surgical methods employing fluorescence guided tumor detection could lead to increased negative resection margins (R 0 ) resulting in improved survival rates. Recent clinical studies involving image-guided surgeries have demonstrated the potential of this approach. 15 We have previously reported TLR2 as a bona fide cell surface marker for pancreatic cancer that is highly expressed in 70% of pancreatic tumors but is not highly expressed in surrounding normal pancreas tissue. 16 Fluorescence imaging probes developed using TLR2 specific ligands could be applied to the intraoperative detection of pancreatic tumor margins.
A variety of microbial component derived lipopeptides (LPs) are recognized as TLR2 ligands. For example, mycoplasma produce diacylated MALP-2, Cys(S-[2,3-bisacyloxy-(R)-propyl])-Gly-Asn-Asn-Asp-Glu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys, which binds to the TLR2/TLR6 heterodimer. 17 The structure− activity relationships (SAR) of TLR2 binding and stimulation of the immune system for many synthetic LPs are well documented in the literature. Both the well-characterized synthetic di-and triacylated LP ligands, Pam 2 CSK 4 and Pam 3 CSK 4 , bind to internal protein pockets through hydrophilic interactions to selectively induce signaling via the TLR2/TLR6 and TLR2/ TLR1 heterodimers, respectively. 4b,17c,18 In addition to LPs, the serum amyloid A protein (SAA) was recently identified as a potent TLR2 agonist by Cheng et al. and is a major acute-phase protein that is considered to be a marker for inflammatory diseases. 1a,19 TLR2 specific agonist ligands developed herein have potential for use in both the development of targeted agents for the imaging and treatment of pancreatic cancer and as an adjuvant for cancer immunotherapy. In an effort to identify novel TLR2 ligands that are highly potent TLR2 agonists for use in immunotherapy, or ligands with high binding affinity for TLR2 with potential for attachment of imaging contrast and therapeutic agents, we have iteratively synthesized two sets of rationally designed synthetic compounds and investigated their SAR by in vitro functional bioassays, in cyto binding assays, in vivo immune system stimulation, and molecular imaging studies demonstrating tumor specificity. From the crystal structure of TLR2 complexes, it is known that the minimal ligand recognition structure contains a Cys(S-[2,3-bis(palmitoyl)oxy-(R)-propyl] residue.
18d Therefore, we kept this pharmacophore element and made changes to the flexible peptide component. The rationale behind this design strategy was to remove the metabolically unstable peptide and the positively charged tetralysine moiety and substitute them with indifferent and hydrophobic polyethylene glycol chains. The goal of this design strategy was to discover water-soluble ligands without compromising potency, and this was achieved for compounds 10, 11, and 13 (vide infra). Compound 10 has potent bioactivity (EC 50 = 20 nM), high affinity binding (K i = 25 nM), and effective immune system stimulation. After conjugation of a near-infrared fluorescent dye to 10 generating 13, high bioactivity (EC 50 = 34 nM) and binding affinity (K i = 11 nM) were retained, and tumor specificity was observed in vivo by fluorescence imaging of mice bearing TLR2 expressing tumor xenografts. In addition, 10 has a greatly simplified synthesis strategy with improved solubility and a builtin attachment point for imaging contrast and/or a therapeutic moiety.
■ RESULTS

TLR2
Ligand Library Design and Synthesis. Thirteen novel fully synthetic compounds were designed and synthesized to discover novel TLR2 specific ligands with the desired properties of high specificity, high agonist activity, high binding affinity, solubility, and built-in attachment points for conjugation of fluorescent dyes and chelates. Initially, seven compounds (1− 7) based on the structure of the bispalmitoylated 17a Cys(S-[2,3-bis(palmitoyl)oxy-(R)-propyl])-Gly-Asn-Asn-AspGlu-Ser-Asn-Ile-Ser-Phe-Lys-Glu-Lys, were synthesized. Each compound in the set comprised the same scaffold, X-Cys(S-[2,3-bis(palmitoyl)oxy-(R)-propyl])-Gly-Asn-Asn-Asp-Glu-Ser-AsnIle-Ser-Phe-Lys-Glu-Lys-NH 2 , or X-MALP-2, where the X-group represents an N-terminal modification (Table 1 , Supporting Information Figure 5 ). After compounds 1−7 were screened for bioactivity (vide infra), a second set of three analogues (8−10) was designed based on SAR knowledge gained from the first set. The scaffold, Ac-PEGO-Cys(S-[2,3-bis(palmitoyl)oxy-(R)-propyl])-Y, was derived using compound 3's N-terminal modification of the MALP-2 LP that included an acetylated 20-atom ethylene glycol oligomer (PEGO) plus Y modifications at the C-terminus (Table  1) . Compound 8's Y-group modification was derived from a CD14 peptide known to induce the physical proximity of CD14, TLR2, and TLR1. 20 Compound 9's Y-group modification was derived from a S. aureus peptide that should be more acidic or at least neutral compared to the recently identified potent TLR2 agonist serum amyloid A (SAA) by Cheng et al. 1a, 21 To test the importance of the peptide component of MALP-2 in terms of potency, compound 10's Y-group modification was derived from compound 3's structure with the peptide component reduced to a short Gly-DSer linker with a PEGO-NH 2 at the C-terminus to enhance solubility.
Since compound 10 was determined to have the most potent TLR2 bioactivity (vide infra), three final compounds were designed and synthesized to incorporate at the N-terminus, in lieu of the acetyl group, a europium diethylenetriaminepentaacetic acid (Eu-DTPA) chelate (compound 11), 3-mercaptopropionyl residue (Mpr) for attachment to thiol groups (compound 12) , and the near-infrared dye IRDye800CW (LI-COR, Lincoln, NE, U.S.) functionalized with Mpr for attachment (compound 13) (Scheme 1, Table 1 ). Compound 11 was used to determine TLR2 binding affinity via in cyto time-resolved fluorescence (TRF) binding assays. Compound 13 was used for in vivo fluorescence imaging to determine TLR2 specificity and binding.
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In Vitro Functional Bioassay. We developed a functional bioactivity assay to specifically detect intracellular signaling induced by agonist stimulation of the human TLR2 receptor at the cell surface. This assay underwent optimization prior to starting our peptide screenings. Optimal NF-κB induced expression of luciferase led to observed luminescence 48 h after transient transfection and 24 h after ligand stimulation. Luminescence intensity was significantly greater (50-fold, n = 6, p < 0.001) in Pam 3 CSK 4 ligand stimulated HEK-293/hTLR2 cells relative to cells incubated with no ligand (Supporting Information Figure 1C ). The ligand-stimulated parental HEK-293 cells had no measurable luminescence. Hence, the measured luminescence is specifically induced by signaling of TLR2 agonists via the NF-κB pathway.
We initially screened the first set of seven MALP-2 derived compounds (1−7) with N-terminal modifications (Table 1) to determine in vitro TLR2 agonist activity. All seven of the compounds exhibited comparable levels of NF-κB induced luminescence relative to the reference TLR2 agonist ligand controls ( Figure 1A ). The control, Pam 2 CSK 4 , is a synthetic diacylated lipopeptide with the same palmitic acid pharmacophore moiety (Pam2 (S-[2,3-bis(palmitoyloxy)-(R)-propyl])) found in MALP-2. All seven of the compounds elicited an agonist response comparable to that of Pam 2 CSK 4 in the screening assay using the 1 μg/mL concentration.
A second set of analogues (8−10) that retained the N-terminal modification of compound 3, acetylated PEGO, with different Cterminal variations were screened for TLR2 agonist activity (Table 1 ). All three of the compounds exhibited significant luminescence intensity relative to the no-ligand control, comparable to the Pam 3 CSK 4 positive control and significantly more potent than SAA at both 1 and 10 μg/mL (n = 4, p < 0.001) ( Figure 1B ). The fold of enhancement for 8, 9, and 10 vs SAA at 1 μg/mL was 11, 13, and 14, respectively. The fold of enhancement for 8, 9, and 10 at 1 μg/mL vs SAA at 10 μg/mL was 4.2, 4.8, and 5.2, respectively.
The agonist potency of compounds 3, 8−13, Pam 2 CSK 4 , and Pam 3 CSK 4 was characterized over a range of concentrations (0.001 ng/mL to 10 μg/mL) to determine EC 50 values. The resulting normalized dose−response curves generated by measuring the TLR2 agonistic activity for each compound and EC 50 values are reported in Table 2 (n = 6 assays for test compounds and n = 3 assays for control compounds, R 2 > 0.94) (Supporting Information Figure 2 ). Test compounds (3, 8−10) are potent TLR2 agonists with low nanomolar EC 50 values ranging from 20 to 78 nM. Compound 10 had the lowest EC 50 (20 nM) ( Figure 1C ), which is comparable to the EC 50 values for (8-10) with an Ac-PEGO-Cys(S-[2,3-bis(palmitoyl)oxy-(R)-propyl])-Y and SAA for TLR2 agonist activity determined using the functional bioassay. All compounds exhibit high luminescence intensities similar to the TLR2 agonist controls, Pam 2 CSK 4 and Pam 3 CSK 4 , using the HEK-293/hTLR2 cells (n = 3 assays with quadruplicate wells, p < 0.0003). Dose−response curves were generated by measuring the TLR2 agonistic activity for (C) compound 10 and (D) compound 13. Experiments were performed by serially adding (0.001 ng/mL to 10 μg/mL) compound to HEK-293/hTLR2 expressing cells (n > 3 assays with quadruplicate wells, R 2 > 0.98). Figure 2F and 2G). Compounds 11, 12 , and 13 based on the structure of 10 with N-terminal attachments were determined to retain nanomolar TLR2 agonist activity, 204, 39, and 34 nM, respectively (Table 2, Figure 1D , Supporting Information Figure 2D ,E).
In Cyto Binding Assays. Lanthanide-based time-resolved fluorescence (TRF) saturation binding and competition binding assays were performed using TLR2 expressing cell lines. Saturation binding assays determined that the K d for the Eu-DTPA chelate labeled compound 11 was 34, 74, and 78 nM and B max was 114 271, 269 878, and 951 170 AFU for the HEK-293/ hTLR2, SU.86.86, and Capan-I cells, respectively (n > 3 assays per cell line, R 2 > 0.96) (Table 3 , Figure 2A , and Supporting Information Figure 3 ). Competitive binding assays using compound 11 as the competing ligand determined that the K i for compounds 10 and 13 is 25 and 11 nM in the HEK-293/ hTLR2 cell line, respectively, and 91 and 67 nM in the SU.86.86 cell line (n > 4 assays, R 2 > 0.78) (Table 4 , Figure 2B ,C, and Supporting Information Figure 4A ,C). Compound 12 exhibited the highest binding affinity in the SU.86.86 cell line with a K i of 25 nM (n = 4 assays, R 2 = 0.90) (Supporting Information Figure  4B ).
In Vivo Immune Response. Compound 10 was evaluated in vivo as an immune adjuvant using TriVax. This peptide vaccine, comprising synthetic peptide representing CD8+ T cell epitopes (Trp1 455/9M ), TLR agonists that function as potent immunologic adjuvants (compound 10, Pam 2 CSK 4 , or Pam 3 CSK 4 ), and costimulatory anti-CD40 monoclonal antibody (Clone, to generate large numbers of antigen-specific CD8+ T cells capable of recognizing and killing tumor cells. 11, 12 For comparison, the well-characterized commercially available synthetic TLR2 agonists, Pam 2 CSK 4 and Pam 3 CSK 4 , were also evaluated for their ability to function as immulogic adjuvants of this peptide vaccine. The activity of each compound as an immune adjuvant was evaluated in vivo by measuring the Trp1 455/9M -specific CD8+ T cell responses in the blood on days 7, 21, and 34 after immunization by flow cytometry analysis (n = 3) ( Figure 3A ). Trp1 455/9M , a TLR agonist, was tested using the TLR2 functional bioassay and is not a TLR2 agonist (data not shown). The maximum amount of fluorescently stained tetramer positive CD8+ T cells for 10, Pam 2 CSK 4 , and Pam 3 CSK 4 observed on day 7 was 49.6%, 56.6%, and 51.7%, respectively. The 100% response rate of the tetramer positive CD8+ T cells using 10 as the immune adjuvant observed on day 7 decreased to an average of 25.7% on day 21 and 12.7% on day 34, which were comparable responses to using either Pam 2 CSK 4 or Pam 3 CSK 4 ( Figure 3B ). Therefore these results indicate that compound 10 exhibited activity similar to those of the other known TLR2 agonists, Pam 2 CSK 4 and Pam 3 CSK 4 , for the generation and persistence of antigen-specific CD8+ T cells. No signs or symptoms of stress or toxicity were observed in the mice over the course of the experiment.
In Vivo Tumor Selectivity. Compound 13, a conjugate with a near-infrared fluorescent dye, IRDye800CW, was used to determine in vivo TLR2 binding and selectivity for TLR2 expressing tumor xenografts (SU.86.86 cells). At 24 h after injection, in vivo fluorescence imaging detected retention of fluorescence signal in the tumor ( Figure 4A ). To determine the in vivo selectivity of 13 for TLR2, a blocking study was performed. A significant reduction in the tumor fluorescence was observed 24 h after injection in the blocked group that received a 20-fold excess of Pam 2 CSK 4 co-injected with 13 compared to the unblocked group receiving only 13 (p < 0.001, n = 8) ( Figure  4A ,B). The mean unblocked tumor fluorescence was 1.94-fold higher than the blocked. Ex vivo imaging confirmed that the fluorescence was associated with the tumors and that the blocked tumors had decreased fluorescence compared to the unblocked tumors ( Figure 4C,D) . IHC staining ( Figure 4E ,F) confirmed TLR2 expression in the tumors.
■ DISCUSSION AND CONCLUSIONS
We first investigated the SAR of a set of novel, fully synthetic compounds (1−7) through manipulation at the N-terminal portion of MALP-2 derived LPs to enhance TLR2 specificity, potency, and binding affinity. Our TLR2 functional bioassay determined that these seven compounds had human TLR2 agonist activities comparable to those of the reference compounds Pam 2 CSK 4 and Pam 3 CSK 4 . This result demonstrated that the addition of palmitoyl, fluorescein, Ac-PEGO, AcAha, adapaleneyl, Ac-Aun, and tretinoyl groups on MALP-2 derived LPs did not inhibit agonist activity. The novel TLR2 agonist analogues (8−10) of compound 3 were designed to alter the chemical properties of the parent compound in order to identify SAR that contributes to increased specificity and binding affinity. This set of compounds was derived from different origins with the goal of altering the compound properties to be more hydrophilic and soluble. Attachment of a modified CD14 peptide (8) or the linker GlyDSer-PEGO-NH 2 (10) was found to enhance the potency, with EC 50 values of 25 and 20 nM, respectively, compared to 3 (EC 50 = 56 nM). The simplest and smallest compound (10) , without inclusion of peptide, had the highest potency. Hence, the palmitoyl groups are the minimal binding/active component, and the PEGO groups or peptides serve solely to increase solubility. The IRDye800CW fluorescent dye attachment (13) also exhibited a potency (EC 50 = 34 nM) similar to that of its unlabeled version (10) , indicating that dye attachment did not significantly decrease TLR2 agonist activity. However, the addition of Eu-DTPA chelate (11) resulted in a 10-fold decrease in potency (EC 50 = 204 nM). Compound 9 was synthesized by attachment of a S. aureus peptide to 3, decreasing the potency (EC 50 = 78 nM). The S. aureus peptide was predicted to be more acidic or at least neutral compared to SAA, with potential to improve potency. Indeed, 9 was observed to have 13-fold higher potency compared to SAA.
The SAR of novel TLR agonist compounds is typically explored using various reporter gene or functional cell-based assays. 22 In order to discover high affinity binding ligands for development of TLR2 targeted agents, we developed a lanthanide-based TRF competition binding assay. We have previously been successful in the characterization of ligand binding affinities for other receptors using this method. 23 For this purpose, compound 11 was synthesized by attachment of Eu-DTPA chelate to the potent TLR2 agonist compound 10. Saturation binding confirmed the high TLR2 binding affinity of 11 (K d < 100 nM), which was then used as the competing ligand in competition binding assays that confirmed the high affinities of compounds 10, 12, and 13 (K i < 100 nM), which also correlated with high agonist potencies. Although 11 exhibited a 10-fold reduction in potency compared to 10, high binding affinity was achieved.
In performing the saturation binding assays with 11, we observed a difference in the K d values obtained in the HEK-293/ hTLR2 cell line, which was genetically engineered to highly overexpress TLR2, compared to the two human pancreatic cells lines SU.86.86 and Capan-1, which express lower endogenous levels of TLR2. 16 Similar results were also seen in the competition binding assays for both 10 and 13, in which a reduction in binding affinity for SU.86.86 cells was observed compared to the engineered cell line. Since these TRF binding assays are performed using living cells and the ligand incubation step is longer than the time needed for receptor mediated uptake, off rates may be reduced in a receptor dependent manner and differences observed in the K d and K i values obtained from the different cell lines are likely due to the varying levels of TLR2 expression.
Using TLR agonists as vaccine adjuvants is a promising application that has been explored to prevent and treat cancer. We have previously reported that the use of TLR agonists as immune adjuvants in peptide vaccination together with anti-CD40 monoclonal antibodies can increase the magnitude and duration of T cell responses resulting from various types of immunizations including peptide vaccines. 10, 11 Results herein show that compound 10 induced an in vivo immune response comparable to the currently available TLR2 synthetic agonists (Pam 2 CSK 4 and Pam 3 CSK 4 ), demonstrating that it can function as an immune adjuvant for use in cancer immunotherapy. Others have also reported that TLR2 agonistic LPs, based on the Pam 2 CS platform, have a potential role as vaccine adjuvants.
24 It is also worth noting that no signs or symptoms of stress or toxicity were observed in the mice over the course of the study. Kimbrell et al. reported that LPs are extremely potent TLR2 agonists in vivo with no apparent toxicity in animal models. 25 The potential use of TLR2 agonist ligands in targeted pancreatic cancer imaging and treatment was explored. We demonstrated the tumor specific retention of the fluorescently labeled compound 13, in vivo, using mice bearing TLR2 expressing xenografts (SU.86.86 cells). Since we previously identified TLR2 as a pancreatic cancer cell surface marker expressed in over 70% of pancreatic tumors but not in normal pancreas tissue, compound 13 could potentially be used for intraoperative detection of pancreatic cancer leading to increased negative resection margins and increased pancreatic cancer survival.
■ EXPERIMENTAL SECTION
Compound Synthesis, Acquisition, and Preparation. Compounds were prepared as previously published by solid-phase synthesis on Rink amide Tentagel resin (0.23 mmol/g) using Fmoc/tBu synthetic strategy and standard DIC-HOBt and HBTU or HCTU activations.
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The synthesis was performed in fritted syringes using a Domino manual synthesizer obtained from Torviq (Niles, MI). For compounds 3 and 8− 13, an Fmoc-protected version of PEGO (Novabiochem, San Diego, CA) was used and an Fmoc protected derivative of Cys, Fmoc-Cys(S-[2,3-bisacyloxy-(R)-propyl])-OH (Fmoc-Dhc(Pam 2 )-OH), was synthesized as described in Supporting Information. 27 All compounds were fully deprotected and cleaved from the resin by treatment with 91% TFA (3% water, 3% EDT, and 3% TA) or 90% TFA (5% water, 5% TIS). After ether extraction of scavengers, compounds were purified by HLPC and/or size-exclusion chromatography (Sephadex G-25, 0.1 M acetic acid) to >95% purity. All compounds were analyzed for purity by analytical HPLC and MS by ESI or MALDI-TOF (synthetic details are in Supporting Information).
Materials. N α -Fmoc protected amino acids, HBTU, and HOBt were purchased from SynPep (Dublin, CA) or from Novabiochem (San Diego, CA). Rink amide Tentagel S resin was acquired from Rapp Polymere (Tubingen, Germany). HOCt, DIC, and DIEA were purchased from IRIS Biotech (Marktredwitz, Germany). The following side chain protecting groups were used for the amino acids: Arg (N gPbf), Asn (N am -Trt), Asp(O-t-Bu), Glu (O-t-Bu), His (N im -Trt), Ser (tBu), DSer (t-Bu), Lys (N ε -Boc). An Fmoc-protected version of PEGO was purchased from Novabiochem. IRDye800CW maleimide was kindly provided by LI-COR (Lincoln, NE). Adapalene was purchased from AK Scientist (aksci.com). Peptide synthesis solvents, dry solvents, and solvents for HPLC (reagent grade), and trans-retinoic acid were acquired from VWR (West Chester, PA) or Sigma-Aldrich (Milwaukee, WI) and were used without further purification unless otherwise noted. Compounds were manually assembled using 5−50 mL plastic syringe reactors equipped with a frit and a Domino manual synthesizer obtained from Torviq (Niles, MI). The C-18 Sep-Pak Vac RC cartridges for solid phase extraction were purchased from Waters (Milford, MA). . An on-resin test using bromophenol blue was used for qualitative and continuous monitoring of reaction progress. To avoid deletion sequences and slower coupling rate in longer sequences, the double coupling was performed at all steps with 3 equiv of amino acid, 3 equiv of HBTU, and 6 equiv of DIEA in DMF. Wherever beads still tested Kaiser positive, a third coupling was performed using the symmetric anhydride method (2 equiv of amino acid and 1 equiv of DIC in dichloromethane). Any unreacted NH 2 groups on the resin thereafter were capped using an excess of 50% acetic anhydride in pyridine for 5 min. When the coupling reaction was finished, the resin was washed with DMF and the same procedure was repeated for the next amino acid until all amino acids were coupled. Fmoc-PEGO, FmocAha, Fmoc-Aun, tretinoic acid, adapalene, and fluorescein were attached to the resin as symmetrical anhydride (6 equiv of acid and 3 equiv of DIC in DCM−DMF).
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Cleavage of Ligand from the Resin. A cleavage cocktail (10 mL per 1 g of resin) of TFA (91%), water (3%), triisopropylsilane (3%), and 1,2-ethylenedithiol (3%) was injected into the resin and stirred for 4 h at room temperature. Alternatively, a cleavage cocktail of 90% trifluoroacetic acid (5% water and 5% triisopropylsilane) was used. The crude ligand was isolated from the resin by filtration. The filtrate was reduced to low volume by evaporation using a stream of nitrogen, and the ligand was precipitated in ice-cold diethyl ether, washed several times with ether, dried, dissolved in water, and lyophilized to give off-white solid powders that were stored at −20°C until purified. The crude compound was purified by size-exclusion chromatography.
Synthesis of Compound 11, Eu-DTPA Labeled Compound. Attachment of DTPA to the N-terminus of was performed using preformed HOBt activation (3 equiv of DTPA anhydride and 6 equiv of HOBt, Scheme 1). DTPA was attached to H-PEGO-Dhc(Pam 2 )-GlyDSer-PEGO resin as follows. Briefly, DTPA anhydride (3 equiv) and HOBt (6 equiv) in DMSO were heated until they were dissolved (60°C ). Then the mixture was stirred for 30 min at room temperature. The preformed DTPA-OBt diester was injected into the free-amine H-PEGO-Dhc(Pam 2 )-Gly-DSer-PEGO resin and stirred overnight. The resin was washed with DMSO, THF, 5% DIEA 5% water in THF (5 min), THF, and DCM. The compound was cleaved from the resin as described above and purified by HPLC. The purified peptide was dissolved in 0.1 M ammonium acetate buffer, pH 8.0. Then 3.0 equiv of Eu(III)Cl 3 was added and the mixture was stirred at room temperature overnight. The Eu-labeled peptide was separated using solid-phase extraction (SPE) and lyophilized to yield an amorphous white powder. The final compound was characterized by HPLC (TEAA buffer, pH 6.0), ESI-MS, and/or FT-ICR.
Synthesis of Compounds 12 and 13. Attachment of Trt-Mpr-OH (S-trityl-3-mercaptopropionic acid) to the N-terminus H-PEGODhc(Pam 2 )-Gly-DSer-PEGO-resin was performed using preformed HBTU activation (3 equiv of Trt-Mpr-OH, 3 equiv of HBTU, and 6 equiv of DIEA in DMF) (Scheme 1). The resin was washed with DMF and DCM. Compound 12 was cleaved from the resin as described above and purified by HPLC.
Compound 12, H-Mpr-PEGO-Dhc(Pam 2 )-Gly-DSer-PEGO-NH 2 (1 μmol), was dissolved in 1 mL of DMF and reacted with 1 equiv of IRDye800CW maleimide under argon atmosphere. The reaction was monitored by HPLC and additional aliquots (0.1 equiv) of dye were added until the reaction was complete. The compound was purified by HPLC. The conjugate, compound 13 (IRDye800CW-Mpr-PEGODhc(Pam 2 )-Gly-DSer-PEGO-NH 2 ), was purified by HPLC.
Purification and Analysis. Purity of the peptides was ensured using analytical HPLC (Waters Alliance 2695 separation model with a dual wavelength detector Waters 2487) with a reverse-phase column (Waters Symmetry, 3.0 mm × 75 mm, 3.5 μm; flow rate of 0.3 mL/min). HPLC conditions were as follows: HPLC, pH 2, linear gradient from 10% to 90% B over 30 min, where A is 0.1% TFA and B is acetonitrile or THF; HPLC pH 6, linear gradient from 10% to 90% B over 30 min, where A is 0.1% TEAA and B is acetonitrile or THF. Size exclusion chromatography was performed on a borosilicate glass column (2.6 mm × 250 mm, Sigma, St. Louis, MO) filled with medium sized Sephadex G-25 or G-10. The compounds were eluted with an isocratic flow of 1.0 M aqueous acetic acid.
Solid-phase extraction was employed where simple isolation of final compound was needed from excess salts and buffers, e.g., for lanthaligand synthesis. For this purpose, C-18 Sep-Pak cartridges (100 or 500 mg) were used and preconditioned initially with 5 column volumes (5 times the volume of packed column bed) each of acetonitrile, methanol, and water, in that order. After the compound was loaded, the column was washed several times with water and then gradually with 5%, 10%, 20%, 30%, 50%, and 70% of aqueous acetonitrile to elute the peptide. Structures were characterized by ESI (Finnigan, Thermoquest LCQ ion trap instrument), MALDI-TOF, or FT-ICR mass spectrometry. An appropriate mixture of standard peptides was used for internal calibrations.
The test compounds (1−13) were dissolved in DMSO at 1 mg/mL as stock solutions stored at −20°C. For biological experimental use, 10 μg/mL working solutions of the compounds were prepared from stock solutions in sterilized, deionized water and used immediately.
Acquisition of Commercially Available Compounds and Antibodies. Commercially available synthetic TLR2 agonists were used as references. Pam 2 CSK 4 and Pam 3 CSK 4 were purchased from InvivoGen (San Diego, CA), and recombinant human apo-SAA1 was purchased from PeproTech (Rocky Hill, NJ).
Trp1 455/9M (TAPDNLGYM) is an H-2D b -optimized peptide for MHC class I binding 28 and was obtained from A&A Labs (San Diego, CA). Rat anti-mouse CD40 monoclonal antibody was prepared from the FGK45.5 hybridoma culture supernatants.
11 FITC-conjugated anti-MHC class II and PerCP Cy5.5-conjugated CD8a antibodies were both purchased from eBioscience (San Diego, CA). Phycoerythrinconjugated Trp1 455/9M /H-2D b tetramers were provided by the NIH Tetramer Facility, Emory University (Atlanta, GA).
Cell Culture. The parental HEK-293 cells (ATCC CRL-1573) and Capan-I cells (ATCC HTB-79) were cultured in DMEM/F12 medium (Life Technologies Gibco) supplemented with 10% normal calf serum (NCS) (Atlanta Biologicals, Lawrenceville, GA) and 1% penicillin/ streptomycin solution (Sigma). The HEK-293/hTLR2 cells (InvivoGen, San Diego, CA) were cultured in DMEM/F12 medium supplemented with 10% NCS, 1% penicillin/streptomycin solution, 10 μg/mL blasticidin (InvivoGen). The SU.86.86 cells (ATCC CRL-1837) were grown in RPMI 1640 medium (Life Technologies Gibco) supplemented with 10% NCS. All cells were grown at 37°C and 5% CO 2 .
The HEK-293/hTLR2 cells were genetically engineered to highly overexpress TLR2 by stable transfection of the parental HEK-293 cells with pUNO-hTLR2 plasmid expressing the human TLR2 gene. 29 The expression of human TLR2 in HEK-293/hTLR2 cells and absence in the parental HEK-293 cells were confirmed by RT-PCR and Western blot analysis (Supporting Information Figure 1A ,B). The two human pancreatic cells lines used in our studies, SU.86.86 and Capan-I, express endogenous levels of TLR2. 16 In Vitro TLR2 Functional Bioassay. The in vitro TLR2 functional bioassay was developed and optimized for use in high-throughput screening of soluble compound libraries to identify both TLR2 agonists and antagonists. The bioassay measures the induction of NF-κB signaling via TLR2 in HEK-293/hTLR2 cells and parental HEK-293 cells as a negative control. Cells were seeded at a density of 40 000 per well using a WellMate microplate dispenser (Thermo Fisher Scientific/ Matrix) in black 96-well plates with opaque white wells (PerkinElmer, Waltham, MA) and then incubated at 37°C. On day 2, the cells were transiently transfected with pNifty-Luc(InvivoGen, San Diego, CA), an NF-κB inducible reporter plasmid expressing the luciferase reporter gene 29 using an optimized 4:1 ratio by volume of FugeneHD transfection reagent (Promega, Madison, WI) to pNifty-Luc plasmid DNA (1 μg/mL). On day 3, the cells were stimulated with either test peptides or controls adjusted to a final concentration of 1 μg/mL using a NanoDrop spectrophotometer, ND1000 (Thermo Fisher Scientific). Synthetic di-and triacylated LP ligands, Pam 2 CSK 4 and Pam 3 CSK 4 (InvivoGen), were used as positive controls. TNF-α (InvivoGen) was also used as a transfection control that induces NF-κB independently of TLR2. On day 4 after 24 h of peptide stimulation, luciferase induced activity by the induction of NF-κB was measured. The medium was aspirated from the wells using an ELx405 SelectCW plate washer (BioTek, Winooski, VT), and 150 μg/mL D-luciferin (Gold Biotechnology, St. Louis, MO) was dispensed using the microplate dispensor. The plates were incubated at 37°C for 5 min. The luminescence intensity was measured using the standard luminescence protocol on a Victor X4 multilabel plate reader equipped with a plate stacker for readout of multiple plates at a time (PerkinElmer, Waltham, MA). For each in vitro TLR2 bioassay, at least three different experiments were performed in triplicate (n ≥ 3). Data were analyzed with GraphPad Prism software, and curves were generated with the appropriate nonlinear fit regression analysis.
In Cyto Europium Time-Resolved Fluorescence Binding Assays. Europium TRF binding assays were performed as previously described with slight modifications using three cell lines that express TLR2: HEK-293/hTLR2, SU.86.86, d, 30 The Capan-I and SU.86.86 cells were plated in 96-well black plates with white opaque wells (PerkinElmer), while the HEK-293/hTLR2 cells were plated on 96-well poly-D-lysine coated plates (Sigma-Aldrich) to aid in the attachment of these cells to the plate. Cells were grown in the 96-well plates for 2 days, reaching approximately 80% confluency. Both types of plates were evaluated for nonspecific binding and background signal.
For saturation binding, increased concentrations of the labeled ligand, compound 11 (Table 3) , were used to determine total binding to TLR2. Nonspecific binding was determined in the presence of 1 μM Pam 2 CSK 4 . On the day of the experiment the medium was aspirated. Then 50 μL of binding buffer was added to the total binding wells and 50 μL of Pam 2 CSK 4 was added to the nonspecific wells and then allowed to incubate for 30 min at 37°C. Next, an amount of 50 μL of the serial dilutions of 10 was added and then allowed to incubate for 1 h at 37°C. Cells were washed three times to remove unbound ligand. Next, 100 μL of DELFIA enhancement solution (PerkinElmer) was added to each well. Cells were incubated for 30 min at 37°C prior to reading. The plates were read on the VICTOR X4 multilabel plate reader using the standard europium TRF protocol (340 nm excitation, 400 μs delay, and 400 μs emission collection at 615 nm). To determine the mean K d , statistical analysis was performed using GraphPad Prism software.
Competition binding assays were performed to test the TLR2 binding specificity of the test ligands using two cell lines: HEK-293/hTLR2 and SU.86.86. Cells were grown in 96-well plates for 2 days, reaching approximately 80% confluency. On the day of the experiment, the cell culture medium was aspirated and 50 μL of nonlabeled test ligand was added in a series of decreasing concentrations (1 μM to 0.01 nM) followed by 50 μL of the competing Eu-labeled ligand 10 at a fixed concentration of 90 nM. Cells were incubated with labeled and unlabeled ligands for 1 h at 37°C. Following incubation, cells were washed three times to remove unbound ligand. Next, 100 μL of DELFIA enhancement solution (PerkinElmer) was added to each well. Cells were incubated for 30 min at 37°C prior to reading. The plates were read on a PerkinElmer VICTOR X4 multilabel reader using the standard europium TRF protocol. To determine the mean K i , statistical analysis was performed using GraphPad Prism software.
Animal Studies. All procedures were in compliance with the Guide for the Care and Use of Laboratory Animal Resources (1996) , National Research Council, and approved by the Institutional Animal Care and Use Committee, University of South Florida. Mice are housed in a clean facility with special conditions that include HEPA filtered ventilated cage systems, autoclaved bedding, autoclaved housing, autoclaved water, irradiated food, and special cage changing procedures. Mice are handled under aseptic conditions including the wearing of gloves, gowns, and shoe coverings.
In Vivo Cellular Immune Response Assays. To assess the efficacy of 10 as an immune adjuvant, we tested it in our previously reported optimized peptide vaccine, TriVax, comprising synthetic peptides, TLR agonists, and anti-CD40 antibodies. 11 The 6−8 week old C57BL/6 (B6) mice (Charles River,Wilmington, MA) were immunized iv with a mixture (in a volume of 200 μL) of 100 μg of optimized Trp1 455 b tetramer positive CD8+ T cells were identified by gating, and analyses were performed using FlowJo software.
In Vivo TLR2 Selectivity Experiment. Female athymic nude mice 6−8 weeks old (Harlan) bearing human pancreatic tumor xenografts consisting of SU.86.86 cells on the right flank were used for this study. Mouse weights and tumor volumes were determined using caliper measurements and the formula volume (mm 3 ) = (length × width 2 )/2. Images were acquired when the tumors reached an average size of 500 mm 3 . For the blocked group, a co-injection of 100 nmol/kg of the fluorescently labeled compound 13 plus 2 μmol/kg Pam 2 CSK 4 (a 20-fold excess) was administered via tail vein injection. For the unblocked group, 100 nmol/kg 13 was administered. Fluorescence images were acquired at 0 and 24 h using the Caliper Xenogen IVIS200 system (PerkinElmer) with the 710−760 nm excitation and 810−875 nm emission filter set. The fluorescence was quantified using Living Image software, in which the quantified signals were corrected for both instrument and mouse background subtractions. The quantified fluorescence was then plotted using GraphPad Prism software and underwent statistical analysis using Student's t test.
For further confirmation of ligand 13 specificity for TLR2, ex vivo fluorescence imaging and histological analyses were performed on the tumors. For histological analyses the samples were fixed in 10% formalin solution, processed, embedded, sectioned, and either H&E stained for the presence of tumor or underwent IHC staining using TLR2 antibody (Abcam no. ab24192).
Statistical Analysis. 
